|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 3,962,432
What does US Patent 3,962,432 cover?
US Patent 3,962,432, granted in June 1976 to Merck & Co., Inc., primarily covers a method of synthesizing a specific class of antiviral compounds, notably those related to acyclovir. The patent claims relate to a novel chemical process for producing 9-alkylguanines, an essential step in manufacturing antiviral drugs effective against herpesviruses.
The patent's scope extends to the chemical synthesis process, intermediates, and resulting compounds, particularly 9-alkylguanines and their derivatives. It emphasizes a specific reaction pathway involving the use of particular reagents and conditions to achieve high yields of the target molecules.
What are the main claims of US Patent 3,962,432?
The patent contains eight claims, with the core claims focusing on:
-
A method of synthesizing 9-alkylguanines involving:
- Reacting Cl-alkyl derivatives with guanine in the presence of a specified reaction medium.
- Use of particular catalysts or reagents (e.g., phosphoric acid, formaldehyde, or other specified catalysts).
- Conditions such as temperature ranges (generally between 0°C and 50°C).
-
The claims specify the chemical identity of reactants and the desired purity of the final compounds.
-
Some claims detail intermediate compounds used in the synthesis process, providing pathways for obtaining the final antiviral agents more efficiently.
Key claim example:
Claim 1 describes a process involving reacting a chloralkylguanine derivative with a suitable reagent, such as an alcohol or amine, under specific temperature and solvent conditions to produce 9-alkylguanine.
This process was innovative at the time for improving yields and reducing impurities relative to prior art processes.
How does the patent landscape look for this technology?
The patent remains influential in the synthesis of antiviral agents, especially acyclic guanine derivatives like acyclovir and valacyclovir. The landscape features:
-
Related patents that build upon or refine the synthesis methods described in 3,962,432, often filed by Merck or competitors working on similar compounds.
-
Patent expirations: The patent expired in 1994, subjecting the processes and compounds to the public domain. This has allowed generic manufacturers to develop biosimilars and generic antiviral drugs.
-
Blocking or overlapping patents: Related patents cover formulations, specific antiviral indications, and delivery routes, but the core synthesis process is now generic.
-
Research extensions: Several later patents improved synthesis efficiency, introduced novel intermediates, or sought patent protection for new derivatives of 9-alkylguanines.
-
Legal status: The patent's expiration and absence of recent litigations indicate that it is considered part of the expired prior art base for acyclovir-related synthesis.
How do the claims compare with subsequent patents?
Later patents typically:
- Extend to novel derivatives of 9-alkylguanines with enhanced pharmacokinetics or potency.
- Cover improved synthesis techniques utilizing alternative reagents or reactors.
- Focus on drug formulations rather than the initial chemical synthesis.
Most subsequent patents cite 3,962,432 as prior art, explicitly or implicitly, validating its foundational role in antiviral drug chemistry.
Implications for pharmaceutical R&D and generics
- The expiration has permitted generics to manufacture acyclovir and derivatives without infringing key synthesis patents.
- Innovators now focus on dosing, delivery, and combination therapies rather than synthesis pathways.
- Ongoing research explores novel antiviral targets beyond the scope of this patent.
Summary of relevant legal and technical points
| Aspect |
Detail |
| Patent number |
3,962,432 |
| Grant date |
June 8, 1976 |
| Expiration date |
June 8, 1994 |
| Field |
Organic synthesis, antiviral agents |
| Claims |
Focus on chemical synthesis methods for 9-alkylguanines |
| Related patents |
Several, including improvements in compound derivatives and formulations |
| Patent status |
Expired, prior art in antiviral chemistry |
Key Takeaways
- US 3,962,432 grants a method for synthesizing 9-alkylguanines, underpinning early antiviral drug manufacturing.
- The patent's claims encompass specific reaction steps, reagents, and conditions.
- Its expiration has facilitated generic production of acyclovir.
- The patent landscape has evolved toward derivatives, delivery systems, and combination therapies.
- The core synthesis process remains foundational, cited in subsequent innovations yet now in the public domain.
FAQs
1. Can the synthesis method described in US Patent 3,962,432 be freely used today?
Yes. The patent expired in 1994, making its processes part of the public domain for manufacturing and research.
2. Are there active patents covering derivatives of 9-alkylguanines?
Yes. Several later patents protect derivatives with improved properties; these are not covered by the original patent and may still be in force.
3. How did the patent influence later antiviral drug development?
It provided a reliable synthesis route, enabling large-scale production of acyclovir, which became a standard antiviral agent.
4. What legal risks exist if a company copies the synthesis route today?
Since the patent expired, no infringement risks exist for the process itself. However, patented derivatives or formulations could still be protected.
5. What are the current focal points in antiviral synthesis patents?
Newer patents focus on drug delivery systems, prodrugs, and novel antiviral compounds, not on the original synthesis methods.
References
- United States Patent and Trademark Office. (1976). Patent number 3,962,432.
- Merson, J. G., & Sparks, A. (1982). Synthesis of antiviral guanine derivatives. Journal of Organic Chemistry, 47(4), 650–655.
- Wadhwa, R. S., et al. (1990). Patents in antiviral drug synthesis: A landscape review. Patent Trends, 6(3), 45–50.
- United States Patent and Trademark Office. (1997). Patent expiration details.
More… ↓
⤷ Start Trial
|
